The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
: Just going back to the analysis that you have on Slide 11, around the lesion growth in the untreated fellow eyes. Can you talk a little bit maybe
about the implications of the differences between what was seen there between DERBY and OAKS? And I guess maybe any conclusions we can
make about how -- what this suggests about kind of the underlying patient population, if at all?
And then just in terms of the exudation, just can you comment maybe on average when time-wise in the studies the exudations were seen and
maybe the -- also the average length of anti-VEGF usage, if patients were able to discontinue anti-VEGF usage?
And then last question, I'm sorry, like logistical one. Sorry if I missed it, but just what percent of the patients on the studies overall have the extrafoveal
lesions versus foveal?
Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
: Sorry, but just in the studies themselves in DERBY and OAKS, what percent, I guess, were extrafoveal versus foveal? Sorry.
Question: Matthew W. Luchini - BMO Capital Markets Equity Research - Analyst
: Two from me, I think. First, just given the stronger effect in extra -- in patients with extrafoveal lesions. Should we then -- I mean, can you comment
on at least if there was a directional benefit in patients -- in foveal patients? And I apologize if I missed that.
And then secondly, going back to the physician feedback that you have heard. Previously today, you've emphasized a lot this idea of kind of a 20%
difference as being the minimum clinically relevant threshold as outlined by your KOL feedback has been an important cutoff. And so I'm just trying
to get a little bit of a gauge on what you're hearing? 17% is obviously close to 20%, but just a little bit more on the actual results here, if you've had
a chance to discuss them.
|
